125 related articles for article (PubMed ID: 31462737)
1. Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.
Ray A; Song Y; Du T; Tai YT; Chauhan D; Anderson KC
Leukemia; 2020 Feb; 34(2):567-577. PubMed ID: 31462737
[TBL] [Abstract][Full Text] [Related]
2. Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.
Ray A; Song Y; Du T; Chauhan D; Anderson KC
Oncogene; 2020 Mar; 39(13):2786-2796. PubMed ID: 32024967
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.
Ray A; Song Y; Du T; Buon L; Tai YT; Chauhan D; Anderson KC
Blood Cancer J; 2022 Apr; 12(4):50. PubMed ID: 35365613
[TBL] [Abstract][Full Text] [Related]
4. Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.
Rad Pour S; Morikawa H; Kiani NA; Yang M; Azimi A; Shafi G; Shang M; Baumgartner R; Ketelhuth DFJ; Kamleh MA; Wheelock CE; Lundqvist A; Hansson J; Tegnér J
Sci Rep; 2019 Aug; 9(1):12150. PubMed ID: 31434983
[TBL] [Abstract][Full Text] [Related]
5. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.
Ray A; Das DS; Song Y; Richardson P; Munshi NC; Chauhan D; Anderson KC
Leukemia; 2015 Jun; 29(6):1441-4. PubMed ID: 25634684
[No Abstract] [Full Text] [Related]
6. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
7. A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.
Ray A; Das DS; Song Y; Macri V; Richardson P; Brooks CL; Chauhan D; Anderson KC
Leukemia; 2017 Dec; 31(12):2652-2660. PubMed ID: 28479592
[TBL] [Abstract][Full Text] [Related]
8. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.
An G; Acharya C; Feng X; Wen K; Zhong M; Zhang L; Munshi NC; Qiu L; Tai YT; Anderson KC
Blood; 2016 Sep; 128(12):1590-603. PubMed ID: 27418644
[TBL] [Abstract][Full Text] [Related]
9. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites.
Terness P; Bauer TM; Röse L; Dufter C; Watzlik A; Simon H; Opelz G
J Exp Med; 2002 Aug; 196(4):447-57. PubMed ID: 12186837
[TBL] [Abstract][Full Text] [Related]
11. Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice.
Tashita C; Hoshi M; Hirata A; Nakamoto K; Ando T; Hattori T; Yamamoto Y; Tezuka H; Tomita H; Hara A; Saito K
World J Gastroenterol; 2020 Mar; 26(9):918-932. PubMed ID: 32206003
[TBL] [Abstract][Full Text] [Related]
12. High-affinity uptake of kynurenine and nitric oxide-mediated inhibition of indoleamine 2,3-dioxygenase in bone marrow-derived myeloid dendritic cells.
Hara T; Ogasawara N; Akimoto H; Takikawa O; Hiramatsu R; Kawabe T; Isobe K; Nagase F
Immunol Lett; 2008 Feb; 116(1):95-102. PubMed ID: 18179826
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan catabolism in IDO+ plasmacytoid dendritic cells.
Fallarino F; Gizzi S; Mosci P; Grohmann U; Puccetti P
Curr Drug Metab; 2007 Apr; 8(3):209-16. PubMed ID: 17430109
[TBL] [Abstract][Full Text] [Related]
15. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
16. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.
Dhodapkar MV; Krasovsky J; Olson K
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13009-13. PubMed ID: 12235374
[TBL] [Abstract][Full Text] [Related]
17. Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c
Woodberry T; Loughland JR; Minigo G; Burel JG; Amante FH; Piera KA; McNeil Y; Yeo TW; Good MF; Doolan DL; Engwerda CR; McCarthy JS; Anstey NM
Infect Immun; 2017 Jun; 85(6):. PubMed ID: 28320838
[No Abstract] [Full Text] [Related]
18. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
19. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
[TBL] [Abstract][Full Text] [Related]
20. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation.
Chen W; Liang X; Peterson AJ; Munn DH; Blazar BR
J Immunol; 2008 Oct; 181(8):5396-404. PubMed ID: 18832696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
